8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Feb 4, 2026·SEC
Material company update
Jan 20, 2026·SEC
enVVeno Medical Corporation(NVNO)Earnings, Financials & Key Ratios
NVNO•NASDAQ
$10.22
$7M mkt cap·Price updated May 7, 2026
AboutenVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.Show more
- Revenue$0
- EBITDA-$20M+12.4%
- Net Income-$19M+10.8%
- EPS (Diluted)-33.06+97.9%
- ROE-56.21%-13.8%
- ROIC-47.33%-13.2%
- Debt/Equity0.03+2.2%
NVNO Key Insights
enVVeno Medical Corporation (NVNO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 99 (top 1%)
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Profits declining 16.3% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NVNO Price & Volume
enVVeno Medical Corporation (NVNO) stock price & volume — 10-year historical chart
Loading chart...
NVNO Growth Metrics
enVVeno Medical Corporation (NVNO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM11.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM52.13%
Return on Capital
10 Years-161.62%
5 Years-55.02%
3 Years-56.7%
Last Year-59.46%
NVNO Recent Earnings
enVVeno Medical Corporation (NVNO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026EPS
$5.89
Est $8.40
+29.9%
Revenue
—
Est $500,000
Q2 2026
Mar 26, 2026EPS
$10.53
Est $9.80
-7.4%
Revenue
—
Est $3M
Q4 2025
Oct 31, 2025EPS
$8.07
Est $10.50
+23.1%
Revenue
—
Q3 2025
Jul 31, 2025EPS
$0.33
Est $0.28
-17.9%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $5.89vs $8.40+29.9% | —vs $500,000 |
| Q2 2026 | Mar 26, 2026 | $10.53vs $9.80-7.4% | —vs $3M |
| Q4 2025 | Oct 31, 2025 | $8.07vs $10.50+23.1% | — |
| Q3 2025 | Jul 31, 2025 | $0.33vs $0.28-17.9% | — |
Based on last 12 quarters of dataView full earnings history →
NVNO Peer Comparison
enVVeno Medical Corporation (NVNO) competitors in Cardiovascular and heart rhythm devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 VNRX | 12.94M | 2.42 | -0.55 | 40.04% | -13.52% | |||
 TELA | 44.38M | 1.10 | -0.83 | 18.56% | -50.61% | -272.13% | 1.51 | |
 NVCR | 1.92B | 16.83 | -13.80 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ANGO | 468.54M | 11.27 | -13.58 | -3.76% | -9.02% | -15.71% | ||
 ELMD | 222.39M | 26.86 | 31.23 | 16.97% | 13.06% | 19.79% | 0.00 | |
 LMAT | 2.46B | 107.91 | 42.82 | 13.53% | 24.35% | 16.19% | 0.47 | |
 ATRC | 1.41B | 27.80 | -115.83 | 14.88% | -0.83% | -0.95% | 0.18 | |
 BSX | 84.08B | 56.58 | 29.16 | 19.87% | 14.4% | 12.4% | 0.51 |
Compare NVNO vs Peers
enVVeno Medical Corporation (NVNO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NVNO Income Statement
enVVeno Medical Corporation (NVNO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 422.11K | 186.55K | 31.24K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -46.29% | -55.81% | -83.25% | -100% | - | - | - | - | - | - |
| Cost of Goods Sold | 558.87K | 0 | 0 | 383.97K | 452.91K | 525K | 546K | 528K | 489K | 367K |
| COGS % of Revenue | 132.4% | - | - | - | - | - | - | - | - | - |
| Gross Profit | -136.76K▲ 0% | 186.55K▲ 236.4% | 31.24K▼ 83.3% | -383.97K▼ 1329.0% | -452.91K▼ 18.0% | -525K▼ 15.9% | -546K▼ 4.0% | -528K▲ 3.3% | -489K▲ 7.4% | -367K▲ 0% |
| Gross Margin % | -32.4% | 100% | 100% | - | - | - | - | - | - | - |
| Gross Profit Growth % | 22.1% | 236.41% | -83.25% | -1328.99% | -17.95% | -15.92% | -4% | 3.3% | 7.39% | - |
| Operating Expenses | 5.97M | 8.04M | 7.71M | 8.75M | 16.44M | 24.41M | 24.69M | 23.3M | 20.41M | 19.64M |
| OpEx % of Revenue | 1413.49% | 4310.51% | 24666.5% | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.32M | 6.35M | 4.51M | 4.5M | 10.71M | 14.49M | 11.11M | 11.05M | 10.92M | 10.22M |
| SG&A % of Revenue | 1259.56% | 3403.63% | 14451.07% | - | - | - | - | - | - | - |
| Research & Development | 649.74K | 1.24M | 2.21M | 4.25M | 5.73M | 9.91M | 13.58M | 12.25M | 9.98M | 9.54M |
| R&D % of Revenue | 153.93% | 664.02% | 7061.17% | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 453.06K | 985.49K | 0 | 0 | 0 | 0 | 0 | -489K | -117K |
| Operating Income | -6.1M▲ 0% | -7.85M▼ 28.7% | -7.68M▲ 2.3% | -9.14M▼ 19.0% | -16.89M▼ 84.9% | -24.93M▼ 47.6% | -25.24M▼ 1.2% | -23.83M▲ 5.6% | -20.9M▲ 12.3% | -20.01M▲ 0% |
| Operating Margin % | -1445.89% | -4210.51% | -24566.5% | - | - | - | - | - | - | - |
| Operating Income Growth % | -30.99% | -28.7% | 2.28% | -19.02% | -84.92% | -47.59% | -1.23% | 5.59% | 12.28% | - |
| EBITDA | -5.96M | -7.72M | -7.28M | -8.75M | -16.44M | -24.41M | -24.69M | -23.3M | -20.41M | -19.64M |
| EBITDA Margin % | -1412.91% | -4138.99% | -23296.89% | - | - | - | - | - | - | - |
| EBITDA Growth % | -32.3% | -29.47% | 5.73% | -20.23% | -87.86% | -48.46% | -1.17% | 5.65% | 12.4% | 13.74% |
| D&A (Non-Cash Add-back) | 139.21K | 133.42K | 396.67K | 383.97K | 452.91K | 525K | 546K | 528K | 489K | 367K |
| EBIT | -5.87M | -6.18M | -7.62M | -9.14M | -16.53M | -24.67M | -23.52M | -21.82M | -20.9M | -15.25M |
| Net Interest Income | -1.92M | -6.86M | 49.91K | 3.74K | 18.71K | 161K | 180K | 389K | 692K | 473K |
| Interest Income | 0 | 0 | 50.85K | 3.74K | 18.71K | 161K | 180K | 389K | 692K | 495K |
| Interest Expense | 1.92M | 6.86M | 933 | -3.74K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -1.69M | -5.19M | 49.91K | -360 | 364.68K | 263K | 1.72M | 2.01M | 1.43M | 1.19M |
| Pretax Income | -7.79M▲ 0% | -13.04M▼ 67.4% | -7.63M▲ 41.5% | -9.14M▼ 19.8% | -16.53M▼ 80.9% | -24.67M▼ 49.3% | -23.52M▲ 4.7% | -21.82M▲ 7.2% | -19.47M▲ 10.8% | -18.82M▲ 0% |
| Pretax Margin % | -1845.83% | -6991.46% | -24406.74% | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -7.79M▲ 0% | -13.04M▼ 67.4% | -7.63M▲ 41.5% | -9.14M▼ 19.8% | -16.53M▼ 80.9% | -24.67M▼ 49.3% | -23.52M▲ 4.7% | -21.82M▲ 7.2% | -19.47M▲ 10.8% | -18.82M▲ 0% |
| Net Margin % | -1845.83% | -6991.46% | -24406.74% | - | - | - | - | - | - | - |
| Net Income Growth % | -32.36% | -67.4% | 41.54% | -19.8% | -80.92% | -49.26% | 4.67% | 7.22% | 10.76% | 11.78% |
| Net Income (Continuing) | -7.79M | -13.04M | -7.63M | -9.14M | -16.53M | -24.67M | -23.52M | -21.82M | -19.47M | -18.82M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -26068.00▲ 0% | -53495.75▼ 105.2% | -14822.50▲ 72.3% | -9236.50▲ 37.7% | -2327.50▲ 74.8% | -2695.00▼ 15.8% | -2339.75▲ 13.2% | -1555.75▲ 33.5% | -33.06▲ 97.9% | -28.77▲ 0% |
| EPS Growth % | -150.35% | -105.22% | 72.29% | 37.69% | 74.8% | -15.79% | 13.18% | 33.51% | 97.88% | 52.13% |
| EPS (Basic) | -26068.00 | -53495.75 | -14822.50 | -9236.50 | -2327.50 | -2695.00 | -2339.75 | -1555.75 | -33.06 | - |
| Diluted Shares Outstanding | 316 | 306 | 515 | 1.05K | 7.09K | 9.17K | 10.04K | 13.99K | 589K | 654K |
| Basic Shares Outstanding | 316 | 306 | 515 | 1.05K | 7.09K | 9.17K | 10.04K | 13.99K | 589K | 654K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NVNO Balance Sheet
enVVeno Medical Corporation (NVNO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 170.41K | 2.84M | 1.42M | 9.57M | 55.04M | 39.44M | 46.92M | 43.73M | 28.83M | 25.49M |
| Cash & Short-Term Investments | 77.69K | 2.74M | 1.31M | 9.33M | 54.73M | 39.04M | 46.41M | 43.15M | 28.21M | 24.93M |
| Cash Only | 77.69K | 2.74M | 1.31M | 9.33M | 54.73M | 4.55M | 3.62M | 1.75M | 3.06M | 2.6M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 34.49M | 42.79M | 41.4M | 25.15M | 22.33M |
| Accounts Receivable | 35.18K | 32.02K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 30.42 | 62.65 | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 57.54K | 64.31K | 116.65K | 234.47K | 312.35K | 392K | 511K | 581K | 614K | 559K |
| Total Non-Current Assets | 2.04M | 722.46K | 2.01M | 968.78K | 2.66M | 2.23M | 1.71M | 1.22M | 736K | 608K |
| Property, Plant & Equipment | 23.84K | 26.15K | 1.17M | 938.94K | 2.6M | 2.19M | 1.68M | 1.19M | 705K | 577K |
| Fixed Asset Turnover | 17.70x | 7.13x | 0.03x | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.11M | 666.47K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 810.05K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 911.22K | 29.84K | 29.84K | 29.84K | 54.49K | 31K | 31K | 31K | 31K | 124K |
| Total Assets | 2.21M▲ 0% | 3.56M▲ 60.7% | 3.43M▼ 3.5% | 10.54M▲ 206.8% | 57.7M▲ 447.5% | 41.66M▼ 27.8% | 48.63M▲ 16.7% | 44.95M▼ 7.6% | 29.56M▼ 34.2% | 26.1M▲ 0% |
| Asset Turnover | 0.19x | 0.05x | 0.01x | - | - | - | - | - | - | 0.00x |
| Asset Growth % | 24.23% | 60.7% | -3.52% | 206.85% | 447.54% | -27.8% | 16.74% | -7.57% | -34.24% | -116.5% |
| Total Current Liabilities | 8.17M | 1.52M | 1.88M | 3.19M | 1.58M | 1.53M | 1.37M | 2.1M | 2.12M | 2.14M |
| Accounts Payable | 1.45M | 1.08M | 1.22M | 1.39M | 560.08K | 648K | 427K | 1.01M | 358K | 0 |
| Days Payables Outstanding | 947.81 | - | - | 1.32K | 451.37 | 450.51 | 285.45 | 695.44 | 267.22 | 511.45 |
| Short-Term Debt | 2.62M | 0 | 0 | 312.7K | 0 | 0 | 0 | 0 | 390K | 396K |
| Deferred Revenue (Current) | 103.4K | 33K | 33K | 33K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.64M | 311.02K | 151.86K | 499.41K | 585K | 450K | 606K | 725K | 1.37M | 1.75M |
| Current Ratio | 0.02x | 1.86x | 0.76x | 3.00x | 34.83x | 25.78x | 34.23x | 20.88x | 13.58x | 13.58x |
| Quick Ratio | 0.02x | 1.86x | 0.76x | 3.00x | 34.83x | 25.78x | 34.23x | 20.88x | 13.58x | 13.58x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 3.18M | 33K | 567.95K | 253.75K | 1.71M | 1.4M | 1.06M | 700K | 310K | 207K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 207K |
| Capital Lease Obligations | 0 | 0 | 567.95K | 253.75K | 1.71M | 1.4M | 1.06M | 700K | 310K | 1.32M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.08M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 8.17M | 1.52M | 2.44M | 3.44M | 3.29M | 2.93M | 2.44M | 2.79M | 2.43M | 2.35M |
| Total Debt | 2.62M | 0 | 856.63K | 880.65K | 2.01M | 1.72M | 1.4M | 1.06M | 700K | 603K |
| Net Debt | 2.54M | -2.74M | -450.6K | -8.45M | -52.72M | -2.84M | -2.22M | -690K | -2.37M | -1.99M |
| Debt / Equity | - | - | 0.87x | 0.12x | 0.04x | 0.04x | 0.03x | 0.03x | 0.03x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.10x |
| Interest Coverage | -3.06x | -0.90x | -8171.99x | -2443.30x | - | - | - | - | - | - |
| Total Equity | -11.13M▲ 0% | 2.04M▲ 118.3% | 989.94K▼ 51.4% | 7.1M▲ 617.0% | 54.4M▲ 666.5% | 38.73M▼ 28.8% | 46.2M▲ 19.3% | 42.16M▼ 8.7% | 27.13M▼ 35.6% | 23.75M▲ 0% |
| Equity Growth % | -163.79% | 118.3% | -51.39% | 617% | 666.49% | -28.81% | 19.29% | -8.75% | -35.65% | -125.45% |
| Book Value per Share | -35222.95 | 6655.04 | 1922.21 | 6734.21 | 7677.70 | 4224.83 | 4600.68 | 3012.86 | 46.06 | 36.31 |
| Total Shareholders' Equity | -11.13M | 2.04M | 989.94K | 7.1M | 54.4M | 38.73M | 46.2M | 42.16M | 27.13M | 23.75M |
| Common Stock | 61 | 117 | 179 | 25 | 95 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -35.52M | -48.56M | -56.19M | -65.32M | -81.85M | -106.52M | -130.04M | -151.85M | -171.33M | -175.18M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -5.17M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NVNO Cash Flow Statement
enVVeno Medical Corporation (NVNO) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.2M | -6.36M | -5.9M | -7.68M | -11.85M | -15.62M | -18.86M | -16.84M | -15.57M | -15.57M |
| Operating CF Margin % | -995.53% | -3407.01% | -18872.71% | - | - | - | - | - | - | - |
| Operating CF Growth % | -36.23% | -51.25% | 7.23% | -30.2% | -54.3% | -31.85% | -20.74% | 10.71% | 7.54% | 54.19% |
| Net Income | -7.79M | -13.04M | -7.63M | -9.14M | -16.53M | -24.67M | -23.52M | -21.82M | -19.47M | -18.82M |
| Depreciation & Amortization | 139.21K | 133.42K | 396.67K | 383.97K | 452.91K | 525K | 546K | 528K | 489K | 491K |
| Stock-Based Compensation | 878.4K | 1.92M | 941.96K | 0 | 6M | 8.99M | 5.2M | 4.14M | 3.42M | 3.24M |
| Deferred Taxes | -231.41K | -1.35M | 588.82K | 0 | -312.7K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.71M | 6.56M | -265.24K | 697.21K | -312.43K | -339K | -468K | 22K | 391K | 217K |
| Working Capital Changes | 1.09M | -578.4K | 66.79K | 377.1K | -1.14M | -130K | -616K | 290K | -396K | 86K |
| Change in Receivables | -11.68K | 3.16K | 32.02K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 90.91K | -217.04K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 545.38K | -294.12K | 144.07K | 169.17K | -832.7K | 88K | -221K | 698K | 1K | 456K |
| Cash from Investing | 165.31K | -12.42K | -363.89K | -180.29K | -367.89K | -34.55M | -7.87M | 1.33M | 15.86M | 13.43M |
| Capital Expenditures | -10.94K | -12.42K | -363.89K | -180.29K | -367.89K | -115K | -33K | -37K | -5K | -5K |
| CapEx % of Revenue | 2.59% | 6.66% | 1164.71% | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 34.44K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 176.25K | 0 | 0 | 0 | 0 | -34.44K | 0 | 0 | 0 | 0 |
| Cash from Financing | 4.06M | 9.03M | 5.64M | 15.07M | 57.61M | 0 | 25.79M | 13.64M | 1.02M | 1.02M |
| Debt Issued (Net) | 2.98M | 2.08M | 0 | 312.7K | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1.29M | 7.66M | 5.64M | 14.76M | 57.36M | 0 | 25.79M | 13.59M | 1.02M | 1.02M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -209.96K | -706.6K | 0 | 0 | 244.89K | 0 | 0 | 46K | 0 | 0 |
| Net Change in Cash | 21.17K▲ 0% | 2.66M▲ 12476.5% | -623.36K▼ 123.4% | 7.22M▲ 1257.8% | 45.39M▲ 528.9% | -50.17M▼ 210.5% | -935K▲ 98.1% | -1.87M▼ 99.6% | 1.31M▲ 170.3% | -340K▲ 0% |
| Free Cash Flow | -4.21M▲ 0% | -6.37M▼ 51.2% | -6.26M▲ 1.7% | -7.86M▼ 25.5% | -12.21M▼ 55.4% | -15.73M▼ 28.8% | -18.89M▼ 20.1% | -16.88M▲ 10.7% | -15.57M▲ 7.7% | -14.79M▲ 0% |
| FCF Margin % | -998.12% | -3413.66% | -20037.42% | - | - | - | - | - | - | - |
| FCF Growth % | -21.83% | -51.15% | 1.7% | -25.51% | -55.44% | -28.82% | -20.06% | 10.67% | 7.72% | 14.66% |
| FCF per Share | -13332.84 | -20811.31 | -12155.90 | -7454.93 | -1723.64 | -1716.37 | -1881.20 | -1205.96 | -26.44 | -26.44 |
| FCF Conversion (FCF/Net Income) | 0.54x | 0.49x | 0.77x | 0.84x | 0.72x | 0.63x | 0.80x | 0.77x | 0.80x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NVNO Key Ratios
enVVeno Medical Corporation (NVNO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -640.47% | -503.93% | -225.91% | -53.75% | -52.98% | -55.38% | -49.39% | -56.21% | -66.39% |
| Return on Invested Capital (ROIC) | - | - | - | - | -7763.98% | -99.54% | -47.4% | -41.82% | -47.33% | -47.33% |
| Gross Margin | -32.4% | 100% | 100% | - | - | - | - | - | - | - |
| Net Margin | -1845.83% | -6991.46% | -24406.74% | - | - | - | - | - | - | - |
| Debt / Equity | - | - | 0.87x | 0.12x | 0.04x | 0.04x | 0.03x | 0.03x | 0.03x | 0.03x |
| Interest Coverage | -3.06x | -0.90x | -8171.99x | -2443.30x | - | - | - | - | - | - |
| FCF Conversion | 0.54x | 0.49x | 0.77x | 0.84x | 0.72x | 0.63x | 0.80x | 0.77x | 0.80x | 0.79x |
| Revenue Growth | -46.29% | -55.81% | -83.25% | -100% | - | - | - | - | - | - |
NVNO SEC Filings & Documents
enVVeno Medical Corporation (NVNO) SEC filings — annual & quarterly reports (10-K, 10-Q)
NVNO Frequently Asked Questions
enVVeno Medical Corporation (NVNO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
enVVeno Medical Corporation (NVNO) grew revenue by 0.0% over the past year. Growth has been modest.
enVVeno Medical Corporation (NVNO) reported a net loss of $18.8M for fiscal year 2025.
Dividend & Returns
enVVeno Medical Corporation (NVNO) has a return on equity (ROE) of -56.2%. Negative ROE indicates the company is unprofitable.
enVVeno Medical Corporation (NVNO) had negative free cash flow of $14.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More NVNO
enVVeno Medical Corporation (NVNO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates